RecruitingNCT07196501
Osavampator or placebo to maintain depression treatment response
About this title
Read the official source — NCT07196501Medication studyAges 18+Multiple countries
Understand this study
Who could participate?
This study is for people with depression. Listed age limits: from 18 years. Other eligibility criteria apply.
- Listed locations
- Oceanside and 60 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: August 18, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 550
- Sponsor
- Neurocrine Biosciences
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Australia, Canada, ...
- Age range
- Over 18 Years
- Official registry ID
- NCT07196501
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Maintenance of Effect of NBI-1065845 as an Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)
Recruitment & locations
RecruitingOceanside, United States · Orange, United States · San Jose, United States
48 more locations
- New Haven, United States
- Miami Gardens, United States
- Orlando, United States
- Palm Bay, United States
- Tampa, United States
- Iowa City, United States
- Marrero, United States
- O'Fallon, United States
- Albuquerque, United States
- Glen Oaks, United States
- Charlotte, United States
- Edmond, United States
- Oklahoma City, United States
- Philadelphia, United States
- Austin, United States
- Bellaire, United States
- Friendswood, United States
- Stafford, United States
- Wichita Falls, United States
- Draper, United States
- Roanoke, United States
- Carlton, Australia
- Melbourne, Australia
- Parkville, Australia
- Sofia, Bulgaria
- Calgary, Canada
- North Vancouver, Canada
- Kingston, Canada
- Sherbrooke, Canada
- Toronto, Canada
- Tallinn, Estonia
- Tartu, Estonia
- Milan, Italy
- Roma, Italy
- Rome, Italy
- Torino, Italy
- Bialystok, Poland
- Bydgoszcz, Poland
- Gdansk, Poland
- Belgrade, Serbia
- Kovin, Serbia
- Kragujevac, Serbia
- Ansan-si, South Korea
- Seoul, South Korea
- Alcorcón, Spain
- Barcelona, Spain
- Keelung, Taiwan
- Taipei, Taiwan
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Neurocrine Biosciences, a biotech company.
Does this study involve medication?
Yes. The study involves medication, including Osavampator and Placebo.
Who can participate?
This study is for people with depression. Listed age limits: from 18 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
